Nano-lateral flow assays for Rapid and Ultra-sensitive Influenza Detection (2017–2021)
Abstract:
Lateral flow assays (LFA), are simple and inexpensive tests for the rapid detection of target biomarkers in biological samples and are used widely in point-of-care diagnostics for infectious disease, pregnancy and fertility testing. The medical technology industry has
identified a need for more sensitive LFA technology for the detection of low abundance disease markers to enable the development of new diagnostic devices. This project will improve LFA detection sensitivity, by developing a next-generation nano-LFA for rapid
and ultra-sensitive disease detection. Purpose-designed mesoporous silica nanoparticles (MSNs) with tuneable structures and surface chemistry will be loaded with quantum dots (QDs) to enhance fluorescence intensity. The optimised nanoparticles will be incorporated with the LFA device developed by our partner (Ellume Pty Ltd) for the rapid detection of influenza. Ellume will contribute $45k cash and ~50k in-kind contributions (e.g. technical
and commercial assistance) to support this fellowship. This project highly aligns with Queensland Science and Research Priority of ¿supporting the translation of health and biotechnology research¿ as it will advance a Queensland technology platform for disease diagnosis, increase Ellume¿s competitiveness in the rapidly growing diagnostics market, create more job opportunities for Queenslanders in the biotechnology sector and reduce
healthcare expenditure.
Grant type:
Advance Queensland Research Fellowships
Funded by:
Queensland Government Department of Science, Information Technology and Innovation
